TAFRO syndrome: current perspectives

References

• CastlemanBIversonLMenendezVPLocalized mediastinal lymphnode hyperplasia resembling thymomaCancer19569482283013356266
   PubMed Web of Science ®Google Scholar
• CastlemanBTowneVWCase records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. CabotN Engl J Med19542511039640013194083
   PubMedGoogle Scholar
• GabaARSteinRSSweetDLVariakojisDMulticentric giant lymph node hyperplasiaAm J Clin Pathol19786918690619617
   PubMed Web of Science ®Google Scholar
• BowneWBLewisJJFilippaDAThe management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literatureCancer199985370671710091744
   PubMed Web of Science ®Google Scholar
• WaterstonABowerMFifty years of multicentric Castleman’s diseaseActa Oncol200443869870415764213
   PubMed Web of Science ®Google Scholar
• KellerARHochholzerLCastlemanBHyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locationsCancer19722936706834551306
   PubMed Web of Science ®Google Scholar
• CroninDMPWarnkeRACastleman disease – an update on classification and the spectrum of associated lesionsAdv Anat Pathol200916423624619546611
   PubMed Web of Science ®Google Scholar
• TakaiKNikkuniKShibuyaHHashidateHThrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegalyRinsho Ketsueki2010515320325 Japanese20534952
   PubMedGoogle Scholar
• KawabataHKadowakiNNishikoriMClinical features and treatment of multicentric Castleman’s disease: a retrospective study of 21 Japanese patients at a single instituteJ Clin Exp Hematop2013531697723801137
   PubMedGoogle Scholar
• ShahidiHMyersJLKvalePACastleman’s diseaseMayo Clin Proc199570109699777564550
   PubMed Web of Science ®Google Scholar
• SoumeraiJDSohaniARAbramsonJSDiagnosis and management of Castleman diseaseCancer Control201421426627825310208
   PubMed Web of Science ®Google Scholar
• DossierAMeigninVFieschiCBoutboulDOksenhendlerEGalicierLHuman herpesvirus 8-related Castleman disease in the absence of HIV infectionClin Infect Dis201356683384223223599
   PubMed Web of Science ®Google Scholar
• LeroySMoshousDCassarOMulticentric Castleman disease in an HHV8-infected child born to consanguineous parents with systematic reviewPediatrics20121291e199e20322157133
   PubMed Web of Science ®Google Scholar
• KishimotoTIL-6: from its discovery to clinical applicationsInt Immunol201022534735220410258
   PubMed Web of Science ®Google Scholar
• StebbingJAdamsCSanittAPlasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman diseaseBlood2011118227127521511959
   PubMed Web of Science ®Google Scholar
• FajgenbaumDCVan RheeFNabelCSHHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapyBlood2014123192924293324622327
   PubMed Web of Science ®Google Scholar
• SudaTKatanoHDelsolGHHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman’s diseasePathol Int200151967167911696169
   PubMed Web of Science ®Google Scholar
• DossierAMeigninVFieschiCBoutboulDOksenhendlerEGalicierLHuman herpesvirus 8-related Castleman disease in the absence of HIV infectionClin Infect Dis201356683384223223599
   PubMed Web of Science ®Google Scholar
• TakaiKNikkuniKMomoiANagaiKIgarashiNSaekiTThrombocytopenia with reticulin fibrosis accompanied by fever, anasarca and hepatosplenomegaly: a clinical report of five casesJ Clin Exp Hematop2013531636823801136
   PubMedGoogle Scholar
• LiuAYNabelCSFinkelmanBSIdiopathic multicentric Castleman’s disease: a systematic literature reviewLancet Haematol201634e163e17527063975
   PubMed Web of Science ®Google Scholar
• NishimotoNSasaiMShimaYImprovement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapyBlood2000951566110607684
   PubMed Web of Science ®Google Scholar
• IwakiNFajgenbaumDCNabelCSClinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman diseaseAm J Hematol201691222022626805758
   PubMed Web of Science ®Google Scholar
• KojimaMNakamuraNTsukamotoNClinical implications of idiopathic multicentric Castleman disease among Japanese: a report of 28 casesInt J Surg Pathol200816439139818499694
   PubMed Web of Science ®Google Scholar
• KawabataHTakaiKKojimaMCastleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a statusJ Clin Exp Hematop2013531576123801135
   PubMedGoogle Scholar
• FajgenbaumDCRuthJRKelleherDRubensteinAHThe collaborative network approach: a new framework to accelerate Castleman’s disease and other rare disease researchLancet Haematol201634e150e15227063967
   PubMed Web of Science ®Google Scholar
• Van RheeFWongRSMunshiNSiltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trialLancet Oncol201415996697425042199
   PubMed Web of Science ®Google Scholar
• FajgenbaumDCUldrickTSBaggAInternational, evidence-based consensus diagnostic criteria for HHV-8 – negative/idiopathic multicentric Castleman diseaseBlood2017129121646165828087540
   PubMed Web of Science ®Google Scholar
• FrizzeraGBanksPMMassarelliGRosaiJA systemic lymphoproliferative disorder with morphologic features of Castleman’s disease. Pathological findings in 15 patientsAm J Surg Pathol1983732112316837832
   PubMed Web of Science ®Google Scholar
• SatoKTsuchiyaMSaldanhaJBendigMMReshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growthCancer Res19935348518568428365
   PubMed Web of Science ®Google Scholar
• KishimotoTInterleukin-6: discovery of a pleiotropic cytokineArthritis Res Ther20068Suppl 2S2
   PubMed Web of Science ®Google Scholar
• Lopez-GironaAMendyDItoTCereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideLeukemia201226112326233522552008
   PubMed Web of Science ®Google Scholar
• StarkeyCRJosteNELeeF-CNear-total resolution of multicentric Castleman disease by prolonged treatment with thalidomideAm J Hematol200681430330416550518
   PubMed Web of Science ®Google Scholar
• TatekawaSUmemuraKFukuyamaRThalidomide for tocilizumab-resistant ascites with TAFRO syndromeClin Case Reports201536472478
   PubMed Web of Science ®Google Scholar
• OcioEMSanchez-GuijoFMDiez-CampeloMEfficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomenaAm J Hematol200578430230515795923
   PubMed Web of Science ®Google Scholar
• GholamDVantelonJ-MAl-JijakliABourhisJ-HA case of multicentric Castleman’s disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibodyAnn Hematol2003821276676812898190
   PubMed Web of Science ®Google Scholar
• ChronowskiGMHaCSWilderRBCabanillasFManningJCoxJDTreatment of unicentric and multicentric Castleman disease and the role of radiotherapyCancer200192367067611505414
   PubMed Web of Science ®Google Scholar
• HessGWagnerVKreftAHeusselCPHuberCEffects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman diseaseBr J Haematol2006134554454516856889
   PubMed Web of Science ®Google Scholar
• SobasMAVenceNAAriasJDLopezABRodriguezMFLopezJLBEfficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant)Ann Hematol201089221721919636554
   PubMed Web of Science ®Google Scholar
• JuvekarAMannaSRamaswamiSBortezomib induces nuclear translocation of IB resulting in gene-specific suppression of NF-B-dependent transcription and induction of apoptosis in CTCLMol Cancer Res20119218319421224428
   PubMed Web of Science ®Google Scholar